Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Rank in Stocks #26670
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Share Price
$5.54
Last synced: 2024-09-18
Market Cap
$38.76M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alimera Sciences, Inc. (ALIM)

Category

Earnings for Alimera Sciences, Inc. (ALIM)
Earnings in Jun 2024 TTM: $-14.71M
According to Alimera Sciences, Inc. latest financial reports the company's current earnings are $-14.71M. In 2022 the company made an earning of $-18.08M, a decrease compared to its 2021 earnings that were of $-3.93M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Alimera Sciences, Inc. from 2006 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-14.71M -26.61%
2023 $-20.05M 10.89%
2022 $-18.08M 359.56%
2021 $-3.93M -27.24%
2020 $-5.41M -47.13%
2019 $-10.23M -37.17%
2018 $-16.28M -25.47%
2017 $-21.84M -33.83%
2016 $-33.00M 8.15%
2015 $-30.52M -14.61%
2014 $-35.74M -22.70%
2013 $-46.23M 134.12%
2012 $-19.75M -12.30%
2011 $-22.52M 32.74%
2010 $-16.96M -59.95%
2009 $-42.36M -30.03%
2008 $-60.54M 383.70%
2007 $-12.52M 20.64%
2006 $-10.37M 0.00%
Earnings for similar companies or competitors